Iron oxide nanoparticle probes for target specific MR molecular imaging

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$482,273.00
Award Year:
2009
Program:
STTR
Phase:
Phase I
Contract:
1R41CA137960-01
Agency Tracking Number:
CA137960
Solicitation Year:
2009
Solicitation Topic Code:
n/a
Solicitation Number:
PHS2009-2
Small Business Information
OCEAN NANOTECH, LLC
OCEAN NANOTECH, LLC, 2143 Worth Lane, SPRINGDALE, AR, 72764
Hubzone Owned:
Y
Socially and Economically Disadvantaged:
N
Woman Owned:
Y
Duns:
155516987
Principal Investigator:
Y WANG
(479) 751-5500
AWANG@OCEANNANOTECH.COM
Business Contact:
ALICE BU
(479) 236-7147
AWANG@OCEANNANOTECH.COM
Research Institution:
STANFORD UNIVERSITY

STANFORD UNIVERSITY
340 Panama Street
STANFORD, CA, 94305-6203

Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): This NIH SBIR project intends to develop a new generation of iron oxide nanoparticles as target specific MRI contrast agents for early detection of breast cancer. Recent advances in iron oxide synthesis in organic solvents at elevated reaction temperature allow the preparation of size tunable and monodisperse particles. These hydrophobic nanoparticles can be converted to water soluble and biolinkable nanoparticles. Our extensive research has demonstrated that these nanoparticles are very stable and can be conjugated to affinity ligands for target specific imaging. Most important, they show little liver uptake but prominent renal uptake. Such phenomenon is vastly different from all literature reported results as all of them have high reticuloendothelial system (RES) uptake in the liver and spleen and none of them has renal clearance due to the relatively large size and agglomeration in vivo. In this Phase I project, we will perform rigorous in vitro, in vivo and ex vivo characterization of various affinity ligand modified iron oxide nanoparticles for targeting integrin 1v23 that is aberrantly expressed on tumor vasculature and invasive tumor cells in breast cancer. In Phase II, focus will be shifted to improving the sensitivity, further reducing reticuloendothelial system (RES) uptake, and studying the toxicity of the proposed probes. The final deliverable of this project is a highly sensitive, clinically applicable MR imaging probe for breast cancer diagnostics. PUBLIC HEALTH RELEVANCE: Breast cancer is the second leading cause of death in the United States. In 2007, about 1,444,920 new cancer cases were expected to be diagnosed, and about 559,650 Americans were expected to die of cancer-more than 1,500 people per day. Enhancing early stage cancer diagnostics is very critical to increase the survival rate of patients. The proposed iron oxide nanoparticle probe as target specific MRI contrast enhancer will provide a platform to detect tumor in its early stage.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government